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ABSTRACT 
Objective: To assess the use of n-of-1 trials for short-term choice of drugs for 
osteoarthritis.  
Design and setting: Evaluation of community-based patients undergoing n-of-
1 trials (double-blind, cross-over comparison of celecoxib 200 or 400 mg daily 
vs sustained-release paracetamol 1330 mg three times daily in three pairs of 
two-week treatment periods with randomization of medication within pairs, with 
the outcomes of pain and stiffness in sites nominated by the patient, functional 
limitation scores, preferred medication, and side effects).  
Participants: Patients with osteoarthritis (with pain for ?1 month) severe 
enough to warrant consideration of long-term use of celecoxib but for whom 
there was doubt about its efficacy. 
Main outcome measures: Changes in drug use after an n-of-1 trial. 
Results: 41/59 n-of-1 trials were completed, in which for 33 (80%) the overall 
symptom relief by celecoxib and paracetamol was equivalent. Management 
after the n-of-1 trial was concordant with its result for 19 of these (13 
generally using paracetamol, six celecoxib).  Symptom relief for celecoxib and 
paracetamol was not equivalent for the remaining eight patients: celecoxib 
provided better relief for seven. 
Conclusions: N-of-1 trials provide a rational and effective method to best 
choose drugs for individual with osteoarthritis. Sustained–release 
paracetamol is useful for most patients whose management is uncertain.  
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Introduction 
Osteoarthritis (OA) is one of the ten most disabling diseases in the developed 
world,1 inflicting joint pain and stiffness among 10% of men and 20% of 
women aged 45–60 years in the west.2 This morbidity presents a significant 
healthcare burden and comes at enormous cost, mostly for analgesic and 
anti-inflammatory drugs. Paracetamol, relatively cheap and safe, is the agent 
of first choice of advisory guidelines based on good evidence from trials.3-5 
But NSAIDs are better for some individuals, especially for moderate to severe 
OA pain4 or where the pain is unresponsive to paracetamol.3
One solution for the safety issue seemed to be COX-2 specific NSAIDs, 
which were increasingly used until 2004 when reports of elevated risk of 
cardiovascular events changed this perception.6;7 
Paracetamol has the disadvantage of requiring 4 doses per day to maintain 
therapeutic serum levels. The recent introduction of sustained-release  
paracetamol has reduced this requirement to 3 doses per day.8;9 
There are three published randomised controlled trials comparing 
paracetamol and celecoxib,10-12 but no n-of-1 trials.  These provide empirical 
data of individual responses to treatment. These are within-patient 
randomized, double-blind, cross-over comparisons, in which patients act as 
their own controls, and provide the most rigorous information available for any 
individual patient.13-17 
We investigated how the results of n-of-1 trials influenced drug use in the 
short-term for patients with OA.  
 
Methods 
We offered an n-of-1 service for celecoxib/sustained-release paracetamol 
throughout Australia between December 2003 and December 2004 
communicating (as we have previously described13;18;19) by post, telephone, 
fax and email. The process was similar to requesting a pathology test: we 
sent packs of test medications by post to patients’ family physicians on 
request; patients completed a daily symptom diary; and we followed up 
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patients by telephone, while the clinician continued to provide usual clinical 
care. At the end of the n-of-1 trial diaries were analysed, and a report sent to 
the doctor within two weeks. When the patient next consulted their doctor, the 
results were available to inform management decisions. 
Recruitment was through a network of participating doctors and a print media 
and radio publicity campaign. Potential patients were able to contact our 
service directly, and information packs which we sent out could be taken to 
the doctor for them to request an n-of-1 trial. Eligibility was restricted to adults 
providing written informed consent with a clinical diagnosis of OA pain for at 
least one month of sufficient severity to consider long-term use of anti-
inflammatory drugs or paracetamol. Contra-indications to either of these, or 
sulphas; concomitant disease (such as peptic ulcer, hepatic or renal 
dysfunction) which increases the risk of side-effects; and depot corticosteroid 
injection in the last two months, were exclusions.
Patients took either sustained-release paracetamol (1.33 g 3-times daily) or 
celecoxib (200 mg daily, or 200 mg twice daily for those who were already 
using this dose), and a placebo encapsulated to be identical to the alternative 
drug. There were three comparisons with paired 2-week treatment periods, (a 
total of 12 weeks), each of which was randomly assigned using a computer-
generated schedule.  Patients, doctors and the research assistant were 
blinded to medication order.  We sent the drugs to participants fortnightly in 
pre-prepared blister packs. We recommended tramadol to the doctors for 
‘escape’ analgesia for uncontrolled pain. 
Ethics approval for this study was provided by the University of Queensland 
Human Research Ethics Committee.  
At commencement, patients provided demographic information and a drug 
history; and recorded side effects weekly.  At the end of each treatment 
period they guessed which treatment they had received.  After the n-of-1 trial, 
patients were interviewed by telephone about subsequent management 
decisions.  
We assessed pain and stiffness scores daily with visual analog scales
marked 0 to 10, omitting the first week of data from each period to negate any 
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carry-over effects. We assessed the patient specific functional scale20 using 
up to 5 patient-nominated functions to assess functional limitation on a 0 to 
10 visual analog scale. Differences in mean scores between measurements 
within pairs of periods were analyzed using hierarchical Bayesian random 
effects models.21 Assuming a minimum detectable difference in pain and 
stiffness scores of 1.0,22 a definite response was defined as an adjusted 
mean absolute difference ?1.0, a probable response as a difference of ?0.5 
but <1.0, and all other responses as no difference. Assuming a minimum 
detectable difference in functional limitation scores of 2.0,23 a definite 
response was defined as an adjusted mean absolute difference ?2.0, a
probable response as a difference of ?1.0 but <2.0 and all other responses as 
no different.
At the end of each comparison, we assessed medication preference. A 
definite response was defined as a preference for one medication in all 3
comparisons, a probable response as a preference in 2 comparisons and no 
response as a preference in 0 or 1 comparison. We assessed adverse events 
weekly in each treatment period. Here, a definite response was defined as 
fewer events on one medication in all 3 comparisons, a probable response as 
fewer events in 2 comparisons and no response as fewer events in no 
comparisons or 1 comparison. 
To describe the overall response, we created an aggregate response 
variable, composed from an equally weighted linear combination of the five 
variables (each defined on a 5-point scale from -2 favouring celecoxib to +2
favouring paracetamol). An individual with aggregate response absolute 
value ?6 was considered a definite responder, a value ?3 but <6 was 
considered a probable responder, and a value <3 was considered a non-
responder.
Results 
Recruitment was stopped prematurely in December 2004 because the 
Australian Therapeutic Goods Administration (TGA) directed all research 
involving celecoxib to stop in view of newly learned increased risk of 
cardiovascular events from it.   
We enrolled 79 patients: 20 did not start their n-of-1 trials; (13 because of the 
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TGA directive; two because of a prior recall of rofecoxib (a COX-2 inhibitor in 
the same class); and five for other reasons, mainly sulpha allergies); 18 
completed only one or two comparisons (one because of adverse reactions 
to celecoxib; six severe pain; five the TGA directive; three the large number 
of tablets; and one each because of concern relating to side-effects of 
celecoxib; failure to complete diaries; and impending admission for surgery). 
The mean age of those who withdrew from this study was 61 years, older 
than most.  
 
Doctors proposed nine n-of-1 trials to patients; patients initiated 50 (45 after 
approaching us having heard of the service by advertisements; four heard 
about them from other patients; and one worked in our research building). 
Demographic and clinical characteristics of the 59 enrolled patients were 
unremarkable, Table 1.  
 
Blinding 
The dose of celecoxib used during the celecoxib periods was 200 mg, once 
daily for 32 patients and twice daily for nine patients. Only one of the 41 
patients guessed which medication they were using in 6/6 treatment periods 
correctly; one 5/6; four 4/4; and the remainder 0/6, 1/6 or 2/6 correctly, no 
difference from what could be expected from chance alone.
Pain, stiffness and functional limitation scores 
Of the 41 completers, 12 had detectable differences in pain scores, (10 in 
favour of celecoxib); 14 in stiffness scores, (12 in favour of celecoxib); two in 
functional limitation scores, (both in favour of celecoxib). The number of 
patients with no detectable differences between medications for these scores 
was 24, 22 and 26 respectively (Table 2). 
 
With meta-analysis of all 41 trials, the mean (SD) scores for the group were 
lower for celecoxib by ---( ) for pain, ---( ) for stiffness and ---( ) for functional 
limitation.  
Aggregate response **Should this appear here or after the ‘adverse effect 
results – given that is uses these results too?**
Looking at the whole group, 33 (80%) patients showed no difference in their 
response to the two medications; 5 had responses that were probably better 
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from celecoxib than paracetamol and; one had a response that was probably 
better to paracetamol than to celecoxib. Two patients’ responses were 
definitely better to celecoxib than paracetamol.
Medication preference 
Three patients preferred celecoxib over paracetamol in all three comparisons: 
and five in two of three comparisons. The remaining 33 had no obvious 
preference. 
 
Adverse events 
Only one adverse event—severe foot/ankle swelling on celecoxib—resulted 
in withdrawal. Nine patients reported more adverse events while on 
paracetamol than on celecoxib, and five reported more while on celecoxib 
than on paracetamol. In the other 25 patients there was no difference in the 
prevalence of adverse events reported.  
 
The most common adverse events on celecoxib were headache and loss of 
energy (54%), indigestion (36%) and constipation (32%); on paracetamol they 
were loss of energy (51%), headache (49%) and constipation and indigestion 
(44%) (Table 4).  
 
Adverse events were mild or moderate in 32 patients. The other nine had 
between 1 and 3 severe symptoms, and one had 6 severe symptoms.  One 
patient had tinnitus through the trial on both drugs. Two other patients had 
this with celecoxib only.  Other severe events on celecoxib were trembles, 
upper body rash, loss of energy and indigestion/heartburn.   
 
Two patients had severe loss of energy on paracetamol extend. Other severe 
events on paracetamol extend were dizziness, diarrhoea, restless leg and 
poor concentration. 
 
Aggregate response 
The aggregate response showed no difference in the response to the two 
medications in 33 (80%) patients; five had responses that were probably 
better to celecoxib than paracetamol and; one had a response that was 
probably better to paracetamol than to celecoxib. Two patients’ responses 
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were definitely better to celecoxib than paracetamol. Agreement between all 
pair-wise comparisons of the 5 outcome variables contributing to the 
aggregate response was poor (<0.40), except for that between pain and 
stiffness (=0.80).
Change in drug use after the n-of-1 trial 
Following the n-of-1 trials there was no change in management in 15/41 
(37%) patients; 12/41 (29%) discontinued NSAID/COX-2 inhibitors 
afterwards; paracetamol was added or substituted for 7/41 (17%) patients; 
and paracetamol was discontinued in 6/41 (15%) patients. 
 
Consistency of drug management with the result of the n-of-1 trial 
Among the 33 patients for whom there was no difference between 
medications,  13 were subsequently managed with paracetamol mainly and 
six with COX-2 inhibitors mainly; three switched to NSAIDs, two ceased 
drugs, and the management was unknown for nine. Of the other eight 
patients whose results favoured one or the other drug, six were managed 
consistently with their IMET result. Altogether, in 25/41 (61%) management 
was consistent with their IMET results. 
 
DISCUSSION 
The aggregate results showed that most (80%) patients completing an n-of-1 
trials have a similar response to celecoxib as to paracetamol. Of the 
remainder celecoxib was probably better in most. These findings are hardly 
surprising as they are similar to previous ones for OA.13,14  Caution is 
warranted in generalising these results the broader population of patients with 
OA as they are derived from a population of patients characterised by 
uncertainty about the efficacy of their drugs for them as individuals and so 
may not represent. Likewise, caution applies to interpreting the post-trial 
decisions about medications as the highly publicised problem with COX-2 
inhibitors that occurred simultaneously may have led more patients to stop 
celecoxib than would have otherwise. 
 
The main application of n-of-1 trials in clinical practice could be to guide 
patients in a rational decision about which of a pair of management options 
best favours their chronic disease. These data might help medical services 
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decide to adopt this process. We have shown that for one of the most 
common chronic diseases use of n-of-1 trials is entirely feasible. That they 
are acceptable to many patients can be attested by the fact that they must 
commit to completing daily symptom diaries for 12 weeks. The withdrawal 
rate of 30% is fairly typical of n-of-1 trials (34%, 40% and 37%)13,14;15 and 
indeed typical of many conventional randomised controlled trials.24 
We have shown that use of n-of-1 trials promotes rational management of 
chronic OA. The impact of this useful clinical tool on long-term management 
and subsequent economic consequences needs further evaluation before it 
becomes more widely accepted. 
 
TABLES: 
 
Table 1: Demographic and clinical characteristics of completers, non-
completers and total commencers of the chronic pain IMET.  
 
Table 2. Response status for each of the five outcomes and the aggregate 
response weighting all available outcomes equally (n =41) 
 
Table 3. Global assessment of response based on an aggregate score with equal 
weightings for pain, stiffness, function, preferred drug and adverse events. 
 
Table 4: Regular drug treatment after the n-of-1 trial compared to before  
 
Table 5. Frequency (%) of adverse events during the total treatment period of 
up to 6 weeks on each medication during the n-of-1 trial. Events for each 
medication are counted only once per participant.(n=41) 
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Table 1: Demographic and clinical characteristics of completers, non-
completers and total commencers of the chronic pain IMET.  
 
Variable Completers 
(n = 41 ) 
Non-
completers 
(n = 18 ) 
Total 
(n = 59 ) 
Age  range 
 mean (SD) 
47-80 
65.5 (8.29) 
30-82 
61 (12.28) 
47-82 
64 (9.89) 
Duration of pain range 
(years)   mean (SD) 
1-46 
11 (10.34) 
2-30 
12 (9.47) 
 
1-46 
11 (10.16) 
Frequency (%) n (%)
Sex    
Male 15 (37) 6 (33) 21 (36)  
Female 26 (63) 12 (67) 38 (64) 
Employment status    
Full time employment R
RRRRRRRRR 
6 (15) 1 (6) 7 (12) 
Part time/casual  employment 3 (7) 2 (11) 5 (8) 
Unpaid homemaker/unemployed 3 (7) 2 (11) 5 (8) 
Retired 26 (63) 8 (44) 34 (58) 
Other 3 (7) 2 (11) 5 (8) 
 Not applicable/no response 0 3 (17) 3 (5) 
Marker joint/area    
 Upper limb 8 (20) 2 (11) 8 (14) 
 Lower limb 21 (51) 9 (50) 30 (51) 
 Neck/back 8 (20) 7 (39) 15 (25) 
 Two or more categories 6 (15) 0 6 (10) 
 Unknown 0 0 0 
Pre-IMET regular medication  
Paracetamol alone  1 (2) 0 1 (2) 
NSAID/Cox-2 inhibitor alone  23 (56) 11 (61) 34 (58) 
Paracetamol plus NSAID/Cox-2 
inhibitor  
7 (17) 4 (22) 11 (19) 
Other  4 (10) 0 4 (7) 
No drug  6 (15) 1 (6) 7 (12) 
Unknown 0 2 (11) 2 (4) 
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Table 2. Response status for each of the five outcomes and the aggregate 
response weighting all available outcomes equally (n =41) 
 
celecoxib  long acting paracetamol 
 definitely 
better 
probably 
better 
No 
difference  
probably 
better 
definitely 
better 
Incomplete 
data 
Lower pain 
scores 
2 8 24 0 2 5 
Lower 
stiffness 
scores 
3 9 22 1 1 5 
Lower 
functional 
limitation 
scores 
0 2 26 0 0 13 
Preferred 
medication 
4 5 28 0 0 5 
 
Fewer 
adverse 
events 
7 2 25 4 1 7 
 
Overall 
response 
2 5 33 1 0  
Table 3.  Global assessment of response based on an aggregate score with equal 
weightings for pain, stiffness, function, preferred drug and adverse events. 
 
celecoxib paracetamol 
definitely 
better 
probably 
better 
No 
difference 
probably 
better 
definitely 
better 
 
TOTAL 
Management 
consistent with 
result 
 
1 4 19# 1 0 25 
Management 
inconsistent with 
result 
 
1* 0 3** 0 0 4 
Unknown 
 
0 1 9 0 0 10 
Nil  
 
0 0 2 0 2
Total 
 
2 5 33 1 0 41 
Response status is further categorised according to the consistency of post n-of-1 trial 
management decisions with this global assessment. 
 
*switched to simple analgesics 
**switched to NSAIDs 
#13 patients mainly using paracetamol 
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Table 4:  Regular drug treatment after the n-of-1 trial compared to before  
 
Treatment after the n-of-1 trial 
No
ch
an
ge
NS
AI
D/
Co
x-2
inh
ibi
tor
ad
de
do
rs
ub
sti
tut
ed
Pa
rac
eta
mo
la
dd
ed
or
su
bs
titu
ted
NS
AI
D/
Co
x-2
inh
ibi
tor
dis
co
nti
nu
ed
Pa
rac
eta
mo
ld
isc
on
tin
ue
d
Ot
he
r/u
nk
no
wn
Paracetamol alone (1) 1 0 0 0 0 0 
NSAID/Cox-2 inhibitor alone (23) 9 1 5* 11 0 1 
Paracetamol plus NSAID/Cox-2 inhibitor (7) 1 0 0 1** 6 0 
Other (4) # 1 2 0 0 0 1 
No drug (6) 3 1 2 0 0 0 
 Tr
ea
tm
en
tb
efo
re
the
n-o
f-1
tri
al
Total (41) 15 4 7 12 6 2 
* 4 patients switched from NSAID/cox-2 inhibitor to paracetamol and are also 
counted in the following column 
** This patient ceased paracetamol in addition and is also counted in the 
following column 
# Aropax, glucosamine, tramadol 
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Table 5. Frequency (%) of adverse events during the total treatment 
period of up to 6 weeks on each medication during the n-of-1 trial. 
Events for each medication are counted only once per participant.(n=41) 
 
n (%) 
Adverse event Celecoxib ER paracetamol 
Drowsiness 9 (22) 9 (22) 
Dizziness 6 (15) 6 (15) 
Indigestion 15 (36) 18 (44) 
Heartburn 11 (27) 12 (29) 
Nausea 7 (17) 9 (22) 
Constipation 13 (32) 18 (44) 
Diarrhoea 10 (24) 6 (15) 
Stomach pains 6 (15) 11 (27) 
Vomiting 1 (2) 3 (7) 
Headache 22 (54) 20 (49)  
Loss of energy 22 (54) 21 (51) 
Poor concentration 13 (32) 14 (34) 
Ringing in ears/tinnitus 12 (29) 10 (24) 
Swelling 4 (10) 6 (15) 
Belching 1 (2) 1 (2) 
Trembles 1 (2) 1 (2) 
Aching legs/knees/feet 1 (2) 1 (2) 
Sore oral mucosa 1 (2) 1 (2) 
Skin rash 1 (2) 0 
Sore throat/ears/mouth 1 (2) 0 
Allergic reaction 1 (2) 0 
Bloating  1 (2) 0 
Flatulence 1 (2) 1 (2) 
Tiredness 0  2 (5) 
Teeth grinding 0 1 (2) 
Hand tremor 0 1 (2) 
Restless legs 0 1 (2) 
Poor circulation 0 1 (2) 
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